Voyager Therapeutics (VYGR) Expected to Announce Quarterly Earnings on Wednesday

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $16.58 million for the quarter.

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock traded down $0.04 on Friday, hitting $4.22. 282,597 shares of the company's stock traded hands, compared to its average volume of 365,937. The firm's 50-day moving average price is $5.37 and its two-hundred day moving average price is $6.10. The stock has a market capitalization of $230.54 million, a PE ratio of 5.94 and a beta of 0.91. Voyager Therapeutics has a one year low of $4.00 and a one year high of $10.66.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Cantor Fitzgerald assumed coverage on Voyager Therapeutics in a report on Friday, January 10th. They set an "overweight" rating and a $5.73 price objective for the company. Wedbush reaffirmed an "outperform" rating and set a $9.00 price target (down from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. Citigroup started coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a "buy" rating and a $12.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday, January 27th. Finally, StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics presently has an average rating of "Buy" and a consensus target price of $15.72.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.